Japan Halts Use of Pfizer and sanofi Vaccines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Japan Halts Use of Pfizer and sanofi Vaccines


ePT--the Electronic Newsletter of Pharmaceutical Technology

Japan suspended the use of two pediatric vaccines, one made by Pfizer and one by sanofi, following the deaths of four children in three days. The deaths occurred shortly after vaccination with Pfizer’s Prevenar vaccine (known as Prevnar in the United States) and sanofi’s ActHIB vaccine. Although a panel of experts at Japan’s Health Ministry have found no link between the deaths and vaccination, the suspension will remain in place while further studies are conducted.

Other national regulatory agencies are aware of the situation. In Hong Kong, the Department of Health said in a statement that it has “no record of untoward event report[s] associated with Prevenar, but we will inform all medical practitioners of the Japanese incident and request them to bring up any anomaly detected." sanofi’s vaccine is not used in Hong Kong, but both are widely used in the US. According to Reuters, FDA is monitoring the safety of both vaccines, but has not observed any safety concenrs in the US.

This is not the first time that Prevenar has faced safety suspicions. In 2009, a batch of Prevenar was pulled from the market in the Netherlands following the deaths of three infants after vaccination. In February 2010, however, it was announced that there was no link between the deaths and vaccination.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here